Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.58 |
| ▸ | TMEM97 | Q5BJF2 | 8/20 | 0.58 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18714779 | 0.90 | SIGMAR1 (0.50) | SIGMAR1TMEM97ACKR3KCNH2HDAC1 | |
| SCHEMBL10223590 | 0.81 | KCNH2 (0.64) | SIGMAR1TMEM97ACKR3KCNH2LMNA | |
| SCHEMBL18714772 | 0.80 | SIGMAR1 (0.50) | SIGMAR1TMEM97ACKR3KCNH2LMNA | |
| SCHEMBL1268694 | 0.80 | SIGMAR1 (0.61) | SIGMAR1TMEM97ACKR3ACHE | |
| SCHEMBL18197676 | 0.77 | KDM4E (0.46) | SIGMAR1TMEM97ACKR3HDAC1ACHE | |
| SCHEMBL28049309 | 0.76 | LMNA (0.49) | SIGMAR1TMEM97ACKR3KCNH2LMNA | |
| SCHEMBL25962676 | 0.75 | MEN1 (0.57) | SIGMAR1KCNH2LMNA | |
| SCHEMBL15942946 | 0.74 | SIGMAR1 (0.58) | SIGMAR1TMEM97ACKR3KCNH2LMNA | |
| SCHEMBL11317777 | 0.74 | SIGMAR1 (0.54) | SIGMAR1TMEM97ACKR3KCNH2LMNA | |
| SCHEMBL17372598 | 0.74 | SIGMAR1 (1.00) | SIGMAR1TMEM97ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3150576-B1 | SUBSTITUTED ACETOHYDRAZIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE | INST PHARMACOLOGY & TOXICOLOGY ACADEMY MILITARY MEDICAL SCIENCES PLA CHINA (CN) | 2019-07-10 | — | — | EP | disclosed |
| US-10196346-B2 | Substituted acethydrazide derivative, preparation method and use thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2019-02-05 | — | — | US | disclosed |
| US-20180134653-A1 | SUBSTITUTED ACETHYDRAZIDE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2018-05-17 | — | — | US | disclosed |
| US-20180134653-A1 | SUBSTITUTED ACETHYDRAZIDE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2018-05-17 | — | — | US | disclosed |
| US-20170190656-A1 | A Substituted Acethydrazide Derivative, Preparation Method and Use Thereof | Institute of Pharmacology and Toxicology Academy of Millitary Medical Sciences P.L.A. China (CN) | 2017-07-06 | — | — | US | disclosed |
| US-20170190656-A1 | A Substituted Acethydrazide Derivative, Preparation Method and Use Thereof | Institute of Pharmacology and Toxicology Academy of Millitary Medical Sciences P.L.A. China (CN) | 2017-07-06 | — | — | US | disclosed |
| EP-3150576-A1 | SUBSTITUTED ACETOHYDRAZIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) | 2017-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190656-A1 | A Substituted Acethydrazide Derivative, Preparation Method and Use Thereof | HIF1AN, HIF1A, EGLN3 | SIGMAR1 1828/4885TMEM97 2123/4885ACKR3 997/4885 |
| US-20180134653-A1 | SUBSTITUTED ACETHYDRAZIDE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | HIF1AN, HIF1A, EGLN3 | SIGMAR1 1851/4885TMEM97 1979/4885ACKR3 929/4885 |
| US-10196346-B2 | Substituted acethydrazide derivative, preparation method and use thereof | HIF1AN, HIF1A, EGLN3 | SIGMAR1 1851/4885TMEM97 1979/4885ACKR3 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.